| Symbol | IMMX |
|---|---|
| Name | IMMIX BIOPHARMA, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 11400 WEST OLYMPIC BOULEVARD,SUITE 200, LOS ANGELES, California, 90064, United States |
| Telephone | +1 310 651-8041 |
| Fax | — |
| — | |
| Website | https://www.immixbio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001873835 |
| Description | Immix Biopharma Inc is a clinical-stage biopharmaceutical company developing Tissue-Specific Therapeutics in oncology and inflammation. Additional info from NASDAQ: |
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX
Read moreNew Form SCHEDULE 13G/A - Immix Biopharma, Inc. <b>Filed:</b> 2026-08-13 <b>AccNo:</b> 0001274173-26-000202 <b>Size:</b> 13 KB
Read moreINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX
Read moreIMMX Investors Have Opportunity to Join Immix Biopharma, Inc. Fraud Investigation with SBS Law
Read moreImmix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Read moreImmix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Read moreINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX
Read more(99% Neutral) IMMIX BIOPHARMA, INC. (IMMX) Announces Update on Collaboration with Registrant
Read moreNew Form SCHEDULE 13G/A - Immix Biopharma, Inc. <b>Filed:</b> 2026-06-05 <b>AccNo:</b> 0001274173-26-000156 <b>Size:</b> 12 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07709715 | A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compa… | Phase3 | Light Chain (AL) Amyloidosis | Not_Yet_Recruiting | 2027-01-01 | 2032-12-01 | ClinicalTrials.gov |
| NCT06097832 | Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis | Phase1 | Light Chain (AL) Amyloidosis | Recruiting | 2024-06-05 | 2039-01-01 | ClinicalTrials.gov |
| NCT05840835 | Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Sol… | Phase1 | Advanced Solid Tumor | Unknown | 2023-02-03 | 2024-01-24 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Dara-CyBorD | Other | Phase PHASE3 | Light Chain (AL) Amyloidosis | NOT_YET_RECRUITING | NCT07709715 |
| NXC-201 | Other | Phase PHASE3 | Light Chain (AL) Amyloidosis | NOT_YET_RECRUITING | NCT07709715 |
| IMX-110 combined with Tislelizumab | Other | Phase PHASE1 | Advanced Solid Tumor | UNKNOWN | NCT05840835 |
| NXC-201 CAR-T | Other | Phase PHASE1 | Light Chain (AL) Amyloidosis | RECRUITING | NCT06097832 |
| NXC-201 CAR-T | BIOLOGICAL | Phase PHASE1 | Light Chain (AL) Amyloidosis | RECRUITING | NCT06097832 |
| IMX-110 combined with Tislelizumab | DRUG | Phase PHASE1 | Advanced Solid Tumor | UNKNOWN | NCT05840835 |